Trial Profile
Efficacy and Safety of XM 02 compared to Filgrastim in patients with breast cancer receiving chemotherapy. Multinational, multicentre, randomised, controlled study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jun 2014
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Neutropenia
- Focus Registrational; Therapeutic Use
- Sponsors BioGeneriX; Teva Pharmaceutical Industries
- 25 Jun 2014 New source identified and integrated, ISRCTN: Current Controlled Trials.
- 25 Jun 2014 New trial record
- 18 Nov 2013 According to the Teva Pharmaceuticals media release, the safety of Filgrastim [Granix] was evaluated in this trial and another two phase III trial in patients receiving myelosuppressive chemotherapy.